Trending...
- California: Governor Newsom announces appointments 10.31.2025
- Warrior Foundation Freedom Station Starts Give-A-Thon to Fly Our Warriors "Home for the Holidays!"
- Statement from the Campaign of Theodis Daniel, Republican for U.S. Congress (TX-18)
Presentation will highlight this novel vascular disruptive antioxidant agent for treating wet and dry AMD with potential synergy given concurrent therapies
RIVERSIDE, Calif. - Californer -- Citrus Therapeutics, LLC, a manufacturer of innovative therapies and an early leader in novel multi-pharmacophore agents for AMD treatment, will present on its patent-pending therapeutic agent, CTZ1™, at the OIS XII event on December 2nd in San Diego, CA. CTZ1™ is the first-of-its-kind vascular disruptive agent (VDA) for treating both wet and dry AMD and was selected for this most competitive showcase for emerging ophthalmology and retina therapeutics and devices.
Citrus Therapeutics is also considered for the 2022 Ophthalmology Innovator Award for CTZ1™.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant moiety fused to an angiogenic-modulating activity structure; consequently, this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. CTZ1™ - as a "vascular disruptive agent" - can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
More on The Californer
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.
CTZ1™ makes its debut from Citrus Therapeutics, LLC, based out of Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor.
For more information about CTZ1™ and its applications email salkayali@citrustherapeutics.com
About Citrus Therapeutics
Citrus Therapeutics, LLC is a U.S. company based in Riverside, California, and was formed to develop, research, and promote innovative muti-pharmacophore therapies. To learn more about CTZ1™ as a therapeutic agent for the treatment of Age-Related Macular Degeneration, visit our website here: citrustherapeutics.com
Citrus Therapeutics is also considered for the 2022 Ophthalmology Innovator Award for CTZ1™.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant moiety fused to an angiogenic-modulating activity structure; consequently, this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. CTZ1™ - as a "vascular disruptive agent" - can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
More on The Californer
- Colony Ridge Proudly Supports the All Ears! 2025 Sporting Clays Tournament
- Jacob Emrani Nominated for LA Executive Award
- Massively parallel implementation of nonlinear functions using an optical processor
- California: Governor Newsom proclaims Alzheimer's Disease Awareness Month
- World-leading economy and climate solutions: California's emissions drop in 2023, driven by clean transportation
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.
CTZ1™ makes its debut from Citrus Therapeutics, LLC, based out of Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor.
For more information about CTZ1™ and its applications email salkayali@citrustherapeutics.com
About Citrus Therapeutics
Citrus Therapeutics, LLC is a U.S. company based in Riverside, California, and was formed to develop, research, and promote innovative muti-pharmacophore therapies. To learn more about CTZ1™ as a therapeutic agent for the treatment of Age-Related Macular Degeneration, visit our website here: citrustherapeutics.com
Source: Citrus Therapeutics
Filed Under: Medical
0 Comments
Latest on The Californer
- Dr. Jay A. Johannigman Delivers Lecture at the John R. Border Memorial Lectureship in Buffalo
- Powering the Next Frontier of the $1 Trillion Space Economy: Ascent Solar Technologies (N A S D A Q: ASTI)
- Taikan's T-V856S VMC Earns Prestigious 2025 Vogel Global Pioneer Award
- Flick Truck Accident Law Joins the Commercial Vehicle Safety Alliance to Strengthen Truck Safety Advocacy
- PebblePad Announces Global Partnership with Inside Higher Ed and Times Higher Education
- Jacko Law Group Named Among Best Law Firms® for Corporate Law in San Diego
- Passion Struck Network Debuts: A Creator-First Platform for Purpose-Driven Podcasting and Human Impact
- Revolutionize Your Home Fitness: Introducing the Advanced Foldable Treadmill at Competitive $499.99
- California: As Trump abandons people and the planet, Governor Newsom heads to COP30 in Brazil
- The Aligned Woman Is It Well With Your Soul
- Jonathan Malveaux Named Newest Member of Forbes Business Council
- The Hangover: Post November 4th Blues
- Divine Logic Launches Proactive Managed IT Services for Fresno Businesses
- NFL Midseason 2025: Who's for Real and Who's Faking It?
- Silver Ball, Golden Heart: Dallas-Area Pinball Wizards Flip for Charity at Side Quest Arcade
- Sweet Beginnings: Sugar Queen Dessert Shop Opens in the Colony Ridge Community
- World Record Established: Million-Dollar Bilibin Screen Sells at Shapiro Auctions
- SEEAG's "Christmas On The Ranch" Offers Fresh-Cut Christmas Trees From Northern California
- PJHM Architects Honored with Outstanding Project Award for Patrick Henry High School Design
- Gold Standard Diagnostics Launches AIX1000 2.1® with Extra High Titer RPR Testing